ClinicalTrials.gg
Status unknownNCT02771509Updated Jul 15, 2021

Study to Prevent Acute Kidney Injury After Cardiac Surgery Involving Cardiopulmonary Bypass

A Phase 2 interventional study of ANG-3777 and Placebo in Acute Kidney Injury, sponsored by Angion Biomedica Corp. Status unknown at 40 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-15.

Sponsored by Angion Biomedica Corp · Phase 2, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Jul 2021), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Phase 2
Study type
Interventional
Enrollment
275
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objective of the study is to assess the safety and efficacy of ANG-3777 in preventing AKI compared to placebo when administered to patients at risk for developing acute kidney injury (AKI) following cardiac surgical procedures involving cardiopulmonary bypass (CPB).

02

Conditions studied

  • Acute Kidney Injury

Browse trials for

Keywords

  • CPB
  • Cardiac Surgery
  • Acute Kidney Injury
03

In context

Acute Kidney Injury

1,691 studies on the registry are indexed under Acute Kidney Injury; 395 are open to participants now.

This study's enrollment of 275 is above the median of 100 across 817 interventional studies indexed under Acute Kidney Injury.

Browse Acute Kidney Injury studies →

Lead sponsor

Angion Biomedica Corp is the lead sponsor of 12 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is either male or female ≥ 18 years.
  2. Patient has provided written , and is willing and able to comply with the requirements of the study protocol, including screening procedures.
  3. Patient must be scheduled for and undergo a non-emergent cardiac surgical procedure involving CPB. Eligible procedures include:

    1. Coronary artery bypass graft (CABG) alone
    2. Aortic valve replacement or repair alone, with or without aortic root repair
    3. Mitral, tricuspid, or pulmonic valve replacement or repair alone
    4. Combined replacement of several cardiac valves
    5. CABG with aortic, mitral, tricuspid, or pulmonic valve replacement or repair
    6. CABG with combined cardiac valve replacement or repair.
  4. Patient must have the following risk factor(s) for AKI prior to surgery:

    1. Estimated (eGFR) of ≥ 20 and \< 30 ml/min/1.73m2, or
    2. eGFR ≥ 30 and \< 60 mL/min/1.73m2 and ONE of the following Additional Risk Factors (other than age ≥ 75 years), or
    3. eGFR ≥ 60 ml/min/1.73m2 and TWO of the following Additional Risk Factors

    eGFR will be calculated using the abbreviated MDRD equation (MDRD-4, often referred to as the Levey equation): eGFR = 186.3 x sCr-1.154 x Age-0.203 x [0.742 if Female] x [1.212 if Black]

    Additional Risk Factors:

    • Combined valve and coronary surgery
    • Previous cardiac surgery with sternotomy
    • (LVEF) \< 35% by invasive or noninvasive diagnostic cardiac imaging within 90 days prior to surgery
    • Diabetes mellitus requiring insulin treatment
    • Non-insulin-requiring diabetes with documented presence of at least moderate (+2 or > 100 mg/dL) proteinuria on urine analysis (medical history or dipstick)
    • Documented Class III or IV within 1 year prior to index surgery
    • Age ≥ 75 years can be considered an Additional Risk Factor only for patients with eGFR ≥ 60 ml/min/1.73m2.
  5. Patient must have presented for surgery without prior evidence of active renal injury defined as no acute rise in sCr > 0.3 mg/dL or no 50% increase in sCr between the time of Screening and pre-surgery.
  6. Patient's (BMI) \< 40 at Screening.

Exclusion criteria

Exclusion Criteria:

  1. Patient has \< 20 mL/min/1.73 m2 within 48 hours pre-surgery as measured by MDRD 4.
  2. Patient has ongoing sepsis or partially treated infection. Sepsis is defined as the presence of a confirmed pathogen, along with fever or hypoperfusion (i.e., acidosis and new onset elevation of liver function tests) or hypotension requiring pressor use prior to surgery.
  3. Currently active infection requiring antibiotic treatment.
  4. Patient who has an active (requiring treatment) or history within 5 years prior to enrollment in the study, of solid, or hematologic malignancy with the exception of basal or squamous cell carcinoma of the skin that has been removed.
  5. Administration of iodinated contrast material within 24 hours prior to cardiac surgery.
  6. Patients diagnosed with AKI as defined by KDIGO criteria within 48 hours prior to surgery.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
275 participants (actual)

Study arms

  • Active comparator
    ANG-3777

    Study drug will be administered for a total of 4 daily intravenous (IV) infusions. The first post-operative dose MUST be started within 4 hours of completing CPB. The second dose will be administered 24 ± 2 hours after completing CPB, and the third and fourth doses will be administered 24 ± 2 hours after each previous dose. Duration of administration is 30 minutes.

    Drug: ANG-3777

  • Placebo comparator
    Normal Saline

    The placebo will be administered for a total of 4 daily intravenous (IV) infusions. The first post-operative dose MUST be started within 4 hours of completing CPB. The second dose will be administered 24 ± 2 hours after completing CPB, and the third and fourth doses will be administered 24 ± 2 hours after each previous dose. Duration of administration is 30 minutes.

    Drug: Placebo

Interventions

  • 6 mg/mL BB3, IV, 4 days in a row, first dose must be within 4 hours after surgery, the next three doses will be approx. 24 hours after the last dose

    Also known as: Hepatocyte growth factor mimetic

  • DrugPlacebo

    Normal saline

    Also known as: Normal Saline

06

What researchers measure

Primary outcomes

  1. The mean AUC of the percent increase in serum creatinine above baseline

    Time frame: starting from 24 hr after the end of CPB through Day 6

07

Study locations

40 sites
  • University of Southern California
    Los Angeles, California 90033, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Stanford University Medical Center
    Palo Alto, California 94304, United States
  • California Institute of Renal Reseach
    San Diego, California 92123, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06520, United States
  • Fleming Island Center for Clinical Research
    Fleming Island, Florida 32207, United States
  • UF Health at Unviersity of Florida
    Gainesville, Florida 32610, United States
  • River City Clinical Research
    Jacksonville, Florida 32207, United States
  • Indiana Ohio Heart
    Fort Wayne, Indiana 46804, United States
  • University of Maryland Medical Center
    Baltimore, Maryland 21201, United States
  • Suburban Hospital
    Bethesda, Maryland 20814, United States
  • MidMichigan Medical Center Midland
    Midland, Michigan 49770, United States
  • Cardiac & Vascular Research Center of Northern Michigan
    Petoskey, Michigan 49770, United States
  • Bryan Heart
    Lincoln, Nebraska 68506, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Duke University
    Durham, North Carolina 27710, United States
  • Wake Forest University School of Medicine
    Winston-Salem, North Carolina 27157, United States
  • TriHealth
    Cincinnati, Ohio 45220, United States
  • Cleveland Clinic Fairview
    Cleveland, Ohio 44111, United States
  • Ohio State Wexner Medical Center
    Columbus, Ohio 43210, United States
  • Baylor Jack and Jane Hamilton Heart and Vascular center- Soltero Cardiovascular Research Center
    Dallas, Texas 75226, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • University of Virginia Health System
    Charlottesville, Virginia 22903, United States
  • Faculdade de Medicina da UNESP Campus de Botucatu
    Botucatu, 18618-686, Brazil
  • Instituto de Cardiologia do Rio Grande do Sul / Fundação Universitária de Cardiologia (IC - FUC)
    Porto Alegre, 90040-371, Brazil
  • Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (HCFMRP)
    Ribeirão Preto, 14048-900, Brazil
  • Fundação Faculdade Regional de Medicina de São José do Rio Preto
    São José Do Rio Preto, 15090-000, Brazil
  • Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (InCor - HCFMUSP)
    São Paulo, 05403-000, Brazil
  • St. John Regional Hospital
    Saint John, New Brunswick E2L 4L2, Canada
  • London Health Sciences Center
    London, Ontario N6A 5A5, Canada
  • Saint Michael's Hospital
    Toronto, Ontario M5B 1W8, Canada
  • CHUM - Hôtel Dieu
    Montréal, Quebec H2W 1T8, Canada
  • MUHC - Royal Victoria Hospital
    Montréal, Quebec H4A 3J1, Canada
  • Institut Universitaire de Cardiologie et de Pneumologie de Québec
    Québec, G1V 4G5, Canada
  • Israeli-Georgian Medical Research Clinic Helsicore
    Tbilisi, 0112, Georgia
  • New Hospitals LTD
    Tbilisi, 0114, Georgia
  • Bokhua Memorial Cardiovascular Center
    Tbilisi, 0159, Georgia
  • Jerarsi JSC
    Tbilisi, 0167, Georgia
  • Tbilisi Heart Center
    Tbilisi, 0186, Georgia
  • Acad. G. Chapidze Emergency Cardiology Center
    Tbilisi, 0519, Georgia
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02771509
Lead sponsor
Angion Biomedica Corp
Collaborators
Everest Clinical Research, CTI Clinical Trial and Consulting Services, Clinical Accelerator
Responsible party
Sponsor
First posted
May 13, 2016
Start date
Feb 24, 2017
Primary completion
Aug 2021 (estimated)
Completion
Aug 2021 (estimated)
Last update
Jul 15, 2021

Study contacts

John Neylan, MD
study director · Angion Biomedica

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Terevalefim

Start the discussion